Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.

10 brokers have issued 1-year price objectives for Madrigal Pharmaceuticals' stock. Their MDGL share price forecasts range from $194.00 to $390.00. On average, they predict the company's stock price to reach $312.36 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.

Madrigal Pharmaceuticals' stock was trading at $290.25 at the start of the year. Since then, MDGL shares have decreased by 7.3% and is now trading at $269.20.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MDGL earnings forecast.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($4.23) earnings per share for the quarter, topping analysts' consensus estimates of ($4.78) by $0.55.

ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Alger Mid Cap 40 ETF (FRTY), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Pharmaceuticals ETF (IHE), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco DWA SmallCap Momentum ETF (DWAS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Madrigal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (9.11%), BlackRock Inc. (5.21%), Perceptive Advisors LLC (3.56%), State Street Corp (2.84%), Assenagon Asset Management S.A. (2.85%) and FMR LLC (1.44%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy.
View institutional ownership trends.

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDGL stock can currently be purchased for approximately $269.20.

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.92 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.10) on an earnings per share basis.

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.